Oncocyte Corp
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
IMDX$2.47-1.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
| Nine Months EndedSeptember 30, | ||
|---|---|---|
| 2024 | 2023 | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net loss | $(27,152) | $(11,789) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization expense | 935 | 1,289 |
| Amortization of intangible assets | 66 | 66 |
| Stock-based compensation | 1,254 | 2,276 |
| Equity compensation for bonus awards and consulting services | 110 | 108 |
| Unrealized gain on marketable equity securities | — | (8) |
| Change in fair value of contingent consideration | 9,421 | (16,947) |
| Impairment losses | — | 6,761 |
| Loss on disposal of discontinued operations | — | 1,521 |
| Impairment loss on held for sale assets | 169 | 1,283 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 275 | 130 |
| Inventories | (232) | — |
| Prepaid expenses and other assets | (345) | 645 |
| Accounts payable and accrued liabilities | 263 | (4,193) |
| Lease assets and liabilities | (123) | (43) |
| Net cash used in operating activities | (15,359) | (18,901) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Proceeds from sale of equipment | — | 354 |
| Construction in progress and purchases of furniture and equipment | (302) | (17) |
| Cash sold in discontinued operations (Note 11) | — | (1,372) |
| Net cash used in investing activities | (302) | (1,035) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from sale of common shares | 15,807 | 13,848 |
| Financing costs to issue common shares | (538) | (427) |
| Proceeds from sale of common shares under at-the-market transactions | 18 | — |
| Financing costs for at-the-market sales | (187) | — |
| Redemption of Series A redeemable convertible preferred shares | (5,389) | (1,118) |
| Repayment of financing lease obligations | (119) | (87) |
| Net provided by financing activities | 9,592 | 12,216 |
| NET CHANGE IN CASH, CASH EQUIVALENTS (INCLUDES DISCONTINUED OPERATIONS) AND RESTRICTED CASH | (6,069) | (7,720) |
| CASH, CASH EQUIVALENTS (INCLUDES DISCONTINUED OPERATIONS) AND RESTRICTED CASH, BEGINNING | 11,132 | 23,203 |
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING | $5,063 | $15,483 |
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION | ||
| Cash paid for interest | $17 | $— |
| Cash paid for income taxes | $— | $— |
| SUPPLEMENTAL SCHEDULE OF NONCASH INVESTING AND FINANCING ACTIVITIES | ||
| Construction in progress, machinery and equipment purchases included in accounts payable and accrued liabilities | $301 | $215 |
| Accretion of Series A convertible preferred stock | $263 | $621 |
| Financing costs for at-the-market sales included in accrued liabilities | $100 | $— |
| Lease assets obtained in exchange for lease liabilities | $1,202 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.